potent, selective, Q2W IV CD73 inhibitor
completed Ph. I in HV, in dev. for cancer imm.
from opt. of known nucleotide CD73 inh.
J. Med. Chem., Jul. 20, 2020
Arcus Biosciences, Hayward, CA
AB680 is a potent (5 pM) and selective inhibitor of CD73, a nucleotidase that metabolizes AMP to immunosuppressive extracellular adenosine. AB680 is intended to be used in combination with checkpoint inhibitor biologics in cancer immunotherapy, and has a PK profile for biweekly (Q2W) IV dosing in humans based on a Ph. I study in healthy volunteers.